8th Meeting Mitochondrial Medicine – Therapeutic Development

18 – 20 March 2024

We are pleased to announce the 8th in our series of meetings on mitochondrial disorders and the search for novel effective therapies.

Mitochondrial disorders have emerged as a major cause of inherited human disease. There is a growing appreciation that new treatments will emerge through collaborations between clinicians, laboratory scientists and the life sciences industry based on a firm understanding of the disease mechanisms. This conference aims to bring these groups together.

The conference will build new partnerships that harness our understanding of the disease mechanisms, accelerating the pace of effective treatments for mitochondrial diseases. This year’s programme will include discussions about recent discoveries on mitochondrial DNA (mtDNA) disorders to develop new therapeutic targets and the latest advances in gene editing and genomic technologies. We will also have panel discussions on how we rally the international community for clinical trial consortia and current opportunities and challenges in clinical trials.

The meeting attracts international participants interested in mitochondrial diseases, working in genomics, biochemistry, pathology and clinical medicine. The conference will bring together leaders in translational mitochondrial medicine and basic science with a programme designed to engage and inspire the next generation of mitochondrial researchers.

The programme will also feature short oral presentations selected from abstracts, posters, poster pitches and networking opportunities. Participants choosing accommodation will stay at Hinxton Hall Conference Centre, Wellcome Genome Campus, to enhance opportunities for interaction after the sessions.


Mitochondrial Medicine – Therapeutic Development, the 8th meeting in this series will take place on 18-20 March 2024.


Michelangelo Mancuso, from University of Pisa, Italy

Nils-Göran Larsson, Karolinska Institute, Sweden (co-organiser)

Rita Horvath, University of Cambridge, UK (co-organiser)

Amel Karaa, Massachusetts General Hospital/Harvard University, USA (co-organiser)

Countries involved:

Sweden, Italy, United Kingdom, USA, the Netherlands, Spain, Australia


Wellcome Genome Campus, Hinxton, United Kingdom.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern